goralatide has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haneda, M; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nitta, K; Shi, S; Srivastava, SP | 1 |
| Azizi, M; Chatellier, G; Lièvre, M; Marre, M; Ménard, J; Peyrard, S | 1 |
1 trial(s) available for goralatide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Guideline Adherence; Humans; Hypertension; Male; Middle Aged; Oligopeptides; Patient Compliance; Physicians; Placebos; Proteinuria | 2006 |
1 other study(ies) available for goralatide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazolidines; Mice; Mice, Inbred NOD; Oligopeptides; Peptidyl-Dipeptidase A | 2016 |